4.1 Acute Otitis Media, Sinusitis & Pharyngitis
Key Takeaways
- Acute otitis media (AOM) requires moderate-to-severe bulging of the tympanic membrane (or mild bulging with otalgia onset <48 hours) for definitive diagnosis; otitis media with effusion (OME) without acute inflammation does not warrant antimicrobial therapy.
- First-line AOM pharmacotherapy is high-dose amoxicillin (80-90 mg/kg/day divided BID) to saturate remodeled penicillin-binding proteins (PBPs 1a, 2b, 2x) in intermediate and resistant Streptococcus pneumoniae strains.
- Amoxicillin-clavulanate for AOM must be prescribed as a 14:1 ratio formulation (90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate) to cover beta-lactamase-producing organisms while avoiding clavulanate-induced secretory diarrhea seen with 4:1 or 7:1 products.
- Antimicrobial duration for AOM is strictly stratified by age and severity: 10 days for children <2 years or severe disease, 7 days for children 2-5 years with mild-to-moderate symptoms, and 5-7 days for children >=6 years.
- Group A Streptococcal (GAS) pharyngitis is treated with penicillin V or oral amoxicillin (50 mg/kg/day once daily, max 1000 mg/day, x 10 days) primarily to prevent acute rheumatic fever, which is achieved when therapy is started within 9 days of symptom onset.
4.1 Acute Otitis Media, Sinusitis & Pharyngitis
Quick Answer: First-line therapy for pediatric acute otitis media (AOM) is high-dose amoxicillin (80–90 mg/kg/day divided BID), designed to overcome altered penicillin-binding proteins in resistant Streptococcus pneumoniae. When beta-lactamase-producing Haemophilus influenzae or Moraxella catarrhalis are suspected (e.g., amoxicillin within 30 days, concurrent purulent conjunctivitis, or treatment failure), switch to amoxicillin-clavulanate in a 14:1 ratio (90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate) to avoid secretory diarrhea. Duration is 10 days for children <2 years, 7 days for ages 2–5, and 5–7 days for ages ≥6. Group A Streptococcal pharyngitis requires 10 days of penicillin V or amoxicillin (50 mg/kg/day once daily) to prevent acute rheumatic fever.
1. Acute Otitis Media (AOM): Diagnostic Criteria & Overview
Acute otitis media is the most common indication for outpatient pediatric antimicrobial prescriptions. The American Academy of Pediatrics (AAP) guideline establishes stringent diagnostic criteria to distinguish true bacterial AOM from otitis media with effusion (OME), preventing unnecessary antibiotic exposure.
Diagnostic Triad for AOM
A definitive diagnosis of AOM requires at least one of the following:
- Moderate-to-severe bulging of the tympanic membrane (TM).
- New-onset otorrhea not attributable to acute otitis externa.
- Mild bulging of the TM accompanied by recent-onset (<48 hours) ear pain (otalgia) or intense erythema of the TM. In non-verbal infants, otalgia presents as ear tugging, holding, rubbing, or excessive unexplained crying.
+-----------------------------------------------------------------------------------------+
| AOM vs OME Differentiation |
+-----------------------------------------------------------------------------------------+
| Feature | Acute Otitis Media (AOM) | Otitis Media with Effusion |
|---------------------------|------------------------------|------------------------------|
| TM Bulging | Moderate to severe bulging | Neutral or retracted TM |
| TM Mobility | Markedly decreased / absent | Decreased mobility |
| Acute Signs/Symptoms | Otalgia, fever, irritability | No acute otalgia or fever |
| Middle Ear Fluid (MEF) | Present | Present |
| Antimicrobial Indication | YES (per age/severity rules) | NO (antibiotics contraindicated) |
+-----------------------------------------------------------------------------------------+
Watchful Waiting (Observation Option)
Antimicrobial therapy can be deferred initially in favor of close observation (watchful waiting for 48–72 hours) with analgesics if all of the following conditions are met:
- Age 6 to 23 months: Unilateral AOM with non-severe symptoms (mild otalgia <48 hours, temperature <39°C / 102.2°F).
- Age ≥24 months: Unilateral OR bilateral AOM with non-severe symptoms.
- Caregiver agreement: Guaranteed rapid follow-up and initiation of antibiotics if symptoms worsen or fail to improve within 48 to 72 hours.
- Mandatory immediate antibiotics: Required for all children <6 months of age, all children with severe symptoms (moderate-to-severe otalgia, otalgia ≥48 hours, or fever ≥39°C), and children aged 6–23 months with bilateral AOM.
2. Microbiology of AOM in the Conjugate Vaccine Era
Widespread adoption of pneumococcal conjugate vaccines (PCV7, PCV13, PCV15, PCV20) has shifted the bacterial distribution of pediatric AOM:
- Haemophilus influenzae (non-typeable, NTHi) (~40–50%): Now the most prevalent isolate in many surveillance cohorts. Approximately 30% to 50% produce beta-lactamases (TEM-1 or ROB-1 enzymes), rendering standard amoxicillin ineffective.
- Streptococcus pneumoniae (~25–35%): Historically the most common pathogen. Although overall rates have declined with PCV vaccination, non-vaccine serotypes persist. Resistant strains harbor altered penicillin-binding proteins (PBPs).
- Moraxella catarrhalis (~10–15%): Virtually >90% to 100% produce beta-lactamases (BRO-1 and BRO-2), but it has a high rate of spontaneous resolution (~50–75%).
- Streptococcus pyogenes (Group A Streptococcus) (~2–5%): More common in school-age children; often associated with TM perforation and severe presentation.
- Viral Pathogens (~20–40% co-infection): RSV, rhinovirus, enterovirus, influenza, and adenovirus frequently precede or co-exist with bacterial AOM, impairing Eustachian tube mucociliary clearance.
3. Pharmacokinetic & Pharmacodynamic Rationale for High-Dose Amoxicillin
Understanding the mechanism of resistance in S. pneumoniae versus H. influenzae is a critical BCPPS board exam competency.
Resistance Mechanism in Streptococcus pneumoniae
- S. pneumoniae does NOT produce beta-lactamases.
- Penicillin resistance is mediated by progressive, cumulative genetic mutations in chromosomal genes encoding penicillin-binding proteins—specifically PBP 1a, PBP 2b, and PBP 2x.
- These remodeled PBPs exhibit dramatically reduced binding affinity for beta-lactam antibiotics. Consequently, the minimum inhibitory concentration (MIC) shifts upward from susceptible (MIC ≤0.06 mcg/mL) to intermediate (MIC 0.12–1 mcg/mL) and resistant (MIC ≥2–4 mcg/mL).
Pharmacodynamic Target: %fT > MIC
Beta-lactams exhibit time-dependent bactericidal killing. The critical pharmacokinetic-pharmacodynamic (PK/PD) predictor of clinical cure is the percentage of time that free (unbound) drug concentration exceeds the MIC of the pathogen (%fT > MIC) in the middle ear fluid (MEF):
+-----------------------------------------------------------------------------------------+
| Standard-Dose vs High-Dose Amoxicillin PK/PD |
+-----------------------------------------------------------------------------------------+
| Parameter | Standard-Dose (40-45 mg/kg/d) | High-Dose (80-90 mg/kg/d) |
|-----------------------------|-------------------------------|---------------------------|
| Peak Serum Concentration | ~4-6 mcg/mL | ~10-14 mcg/mL |
| Peak Middle Ear Fluid (MEF) | ~1-2 mcg/mL | ~3-6 mcg/mL |
| MEF Penetration Ratio | ~20-30% of serum | ~30-40% of serum |
| %fT > MIC (MIC = 2 mcg/mL) | <25% (Clinical failure) | >50% (Bactericidal cure) |
| Target Coverage | Susceptible strains only | Intermediate & resistant |
+-----------------------------------------------------------------------------------------+
High-dose amoxicillin (80–90 mg/kg/day divided every 12 hours, maximum 4000 mg/day) drives peak serum concentrations high enough to force diffusion into the middle ear, exceeding an MIC of 2 mcg/mL for >50% of the 12-hour dosing interval.
4. Beta-Lactamase Coverage & The 14:1 Amoxicillin-Clavulanate Ratio
Indications for Amoxicillin-Clavulanate as First-Line Therapy
Amoxicillin alone does not inhibit beta-lactamases produced by H. influenzae and M. catarrhalis. Amoxicillin-clavulanate is indicated as initial first-line therapy when:
- The child has received amoxicillin in the preceding 30 days (high likelihood of colonization with beta-lactamase-producing NTHi).
- The child presents with concurrent purulent conjunctivitis ("otitis-conjunctivitis syndrome", strongly predictive of NTHi).
- The child has a history of recurrent AOM unresponsive to amoxicillin monotherapy.
The Clavulanate Secretory Diarrhea Trap & The 14:1 Formulation
Clavulanic acid hyperstimulates gastrointestinal motility and induces intestinal hypersecretion. Clinical trials established that diarrhea incidence increases dramatically when the clavulanate dose exceeds 10 mg/kg/day.
+-----------------------------------------------------------------------------------------+
| Amoxicillin-to-Clavulanate Ratio Comparison |
+-----------------------------------------------------------------------------------------+
| Commercial Product | Ratio | Amoxicillin Dose | Clavulanate Dose | Diarrhea Risk |
|---------------------------|-------|------------------|------------------|---------------|
| Augmentin 250 mg/62.5 mg | 4:1 | 90 mg/kg/day | 22.5 mg/kg/day | Extreme (>60%)|
| Augmentin 400 mg/57 mg | 7:1 | 90 mg/kg/day | 12.8 mg/kg/day | High (~30-40%)|
| Augmentin ES-600 (600/42.9)| 14:1 | 90 mg/kg/day | 6.4 mg/kg/day | Low (~10-15%) |
+-----------------------------------------------------------------------------------------+
Board Exam Calculation Pearl: To achieve 90 mg/kg/day amoxicillin and 6.4 mg/kg/day clavulanate without inducing intolerable diarrhea, pharmacists must dispense the 14:1 formulation (Augmentin ES-600: amoxicillin 600 mg / clavulanate 42.9 mg per 5 mL), dosed at 90 mg/kg/day amoxicillin component divided BID taken at the start of a meal.
5. Pediatric Penicillin Allergy Pathways & Alternative Regimens
Penicillin allergy evaluation requires differentiating non-IgE cutaneous reactions from true Type 1 IgE-mediated anaphylaxis.
+-----------------------------------------------------------------------------------------+
| AOM Antimicrobial Selection by Allergy Type |
+-----------------------------------------------------------------------------------------+
| Clinical Scenario | Preferred Regimen | Dosing & Administration |
|----------------------------|---------------------------------|--------------------------|
| No Penicillin Allergy | High-Dose Amoxicillin | 80-90 mg/kg/d divided BID|
| Amoxicillin in last 30d or | High-Dose Amox-Clav (14:1) | 90 mg/kg/d amox with |
| Conjunctivitis | (Augmentin ES-600) | 6.4 mg/kg/d clav BID |
| Non-IgE Penicillin Allergy | Oral 2nd/3rd gen cephalosporin: | |
| (Delayed benign rash) | - Cefdinir | 14 mg/kg/d once daily or BID
| | - Cefuroxime axetil | 30 mg/kg/d divided BID |
| | - Cefpodoxime proxetil | 10 mg/kg/d divided BID |
| Severe / Vomiting / NPO | Ceftriaxone IM/IV | 50 mg/kg/dose once daily |
| or Treatment Failure | | (1 to 3 consecutive days)|
| Severe IgE Allergy | Clindamycin | 30-40 mg/kg/d divided TID|
| (Anaphylaxis, Angioedema) | +/- Cefdinir (if allowed) OR | (Covers resistant pneumo;|
| | Levofloxacin (off-label) | NO H. flu / M. cat cover)|
+-----------------------------------------------------------------------------------------+
Cephalosporin Safety in Non-IgE Penicillin Allergy
Second- and third-generation cephalosporins (cefdinir, cefuroxime, cefpodoxime) possess distinct R1 side-chain structures that do not share cross-reactivity with the ampicillin/amoxicillin side chain. The risk of cross-reactivity in non-severe, delayed reactions is <1%. They are fully endorsed by AAP and IDSA for patients without a history of anaphylaxis, bronchospasm, or severe cutaneous adverse reactions (SCARs/Stevens-Johnson syndrome).
The Clindamycin Coverage Void
Clindamycin (30–40 mg/kg/day divided TID) is active against many penicillin-resistant S. pneumoniae isolates. However, clindamycin has ZERO activity against Gram-negative bacilli, leaving H. influenzae and M. catarrhalis completely uninhibited. If clindamycin is selected for severe pneumococcal AOM, treatment failure will occur if the etiology is NTHi.
6. Treatment Duration by Age and Severity
+-----------------------------------------------------------------------------------------+
| AOM Antimicrobial Treatment Duration |
+-----------------------------------------------------------------------------------------+
| Age Group | Clinical Severity | Recommended Duration |
|----------------------------|---------------------------------|--------------------------|
| < 2 years | Any severity | 10 days |
| 2 to 5 years | Severe (fever >=39C, severe pain)| 10 days |
| 2 to 5 years | Mild to moderate symptoms | 7 days |
| >= 6 years | Severe | 10 days |
| >= 6 years | Mild to moderate symptoms | 5 to 7 days |
+-----------------------------------------------------------------------------------------+
7. Acute Bacterial Rhinosinusitis (ABRS)
Viral upper respiratory infections (URIs) precede ABRS in >90% of cases. Overdiagnosis is frequent. The AAP guideline requires one of three stringent clinical presentations for ABRS diagnosis:
- Persistent Illness: Nasal discharge (any quality) or daytime cough lasting ≥10 days without clinical improvement.
- Worsening Course ("Double Sickening"): Initial signs of a common cold that improve for 3–5 days, followed by sudden high fever, increased nasal discharge, or new cough.
- Severe Onset: Concurrent temperature ≥39°C (102.2°F) AND purulent (thick, colored) nasal discharge for at least 3 consecutive days.
Antimicrobial Management of ABRS
Unlike AOM, where amoxicillin monotherapy is first-line, AAP and IDSA guidelines recommend high-dose amoxicillin-clavulanate (14:1 ratio, 90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate divided BID) as initial first-line therapy for ABRS because H. influenzae and M. catarrhalis isolated from paranasal sinuses exhibit higher baseline beta-lactamase production. Duration: 10 to 14 days.
8. Group A Streptococcal (GAS) Pharyngitis
GAS pharyngitis (Streptococcus pyogenes) accounts for 15% to 30% of acute pharyngitis cases in children aged 5 to 15 years. It is distinctly uncommon in children <3 years of age, in whom routine testing is not recommended.
Diagnosis: RADT and Culture Confirmation
- Perform a Rapid Antigen Detection Test (RADT) on throat swabs taken from the posterior pharynx and tonsils.
- Pediatric Rule: Because RADT has high specificity (≥95%) but variable sensitivity (70–90%), a negative RADT in a child or adolescent MUST be confirmed by a backup throat culture to prevent untreated infection.
- Testing is contraindicated in patients with clear viral symptoms (cough, rhinorrhea, hoarseness, oral ulcers, conjunctivitis).
Therapeutic Objectives: Acute Rheumatic Fever Prevention
The primary objective of antimicrobial therapy in GAS pharyngitis is the prevention of Acute Rheumatic Fever (ARF) and suppurative complications (peritonsillar abscess, retropharyngeal abscess).
Critical Board Pearl: Antibiotic therapy prevents Acute Rheumatic Fever even if started up to 9 days after the onset of acute symptoms. However, antibiotic therapy has NO impact on preventing Post-Streptococcal Glomerulonephritis (PSGN).
+-----------------------------------------------------------------------------------------+
| GAS Pharyngitis Antimicrobial Regimens |
+-----------------------------------------------------------------------------------------+
| Drug | Pediatric Dosing | Frequency & Duration |
|----------------------------|---------------------------------|--------------------------|
| Penicillin V (Oral) | <27 kg: 250 mg/dose | BID or TID x 10 days |
| | >=27 kg: 500 mg/dose | BID or TID x 10 days |
| Amoxicillin (Oral) | 50 mg/kg/day (max 1000 mg/day) | Once daily x 10 days OR |
| (Preferred due to taste) | | 25 mg/kg/dose BID x 10 d |
| Benzathine Penicillin G | <27 kg: 600,000 units | IM single dose |
| (Intramuscular) | >=27 kg: 1,200,000 units | IM single dose |
| Cephalexin (Non-IgE allergy)| 40 mg/kg/day (max 1000 mg/day) | Divided BID x 10 days |
| Cefdinir (Non-IgE allergy) | 14 mg/kg/day (max 600 mg/day) | Once daily x 10 days |
| Azithromycin (Severe allergy)| 12 mg/kg once daily (max 500 mg)| Daily x 5 days |
| Clindamycin (Severe allergy)| 20 mg/kg/day (max 900 mg/day) | Divided TID x 10 days |
+-----------------------------------------------------------------------------------------+
Amoxicillin is widely preferred over penicillin V oral suspension because the amoxicillin suspension has superior palatability, fewer GI side effects, and convenient once-daily dosing (50 mg/kg once daily for 10 days).
9. Practice Management & Pharmacist Monitoring Pearls
- Reconstitution and Storage: Amoxicillin oral suspension is stable for 14 days at room temperature or refrigeration (refrigeration preferred for taste). Augmentin ES-600 suspension MUST be refrigerated and discarded after 10 days. Cefdinir suspension MUST be stored at controlled room temperature (20°C–25°C); refrigeration causes thickening and precipitation.
- Red Stool Discoloration with Cefdinir: When cefdinir binds iron in iron-fortified infant formulas or multivitamins, it forms a non-absorbable red complex that turns stools reddish-rust. Counsel caregivers that this is harmless and not blood.
- Analgesia: Systemic analgesics (acetaminophen 10–15 mg/kg/dose every 4–6 hours, max 75 mg/kg/day; ibuprofen 10 mg/kg/dose every 6 hours, max 40 mg/kg/day in infants ≥6 months) must be optimized within the first 24–48 hours, as antibiotics do not provide immediate pain relief.
A 14-month-old child weighing 10 kg presents with acute otitis media accompanied by bilateral purulent conjunctivitis ('otitis-conjunctivitis syndrome'). The child has not received antibiotics in the past 6 months and has no known drug allergies. Which oral antimicrobial regimen is the most appropriate first-line therapy?
Which statement correctly describes the pharmacokinetic-pharmacodynamic rationale for administering high-dose amoxicillin (80-90 mg/kg/day) rather than standard-dose amoxicillin (40-45 mg/kg/day) in pediatric acute otitis media?
A 7-year-old child presents with a sudden onset of fever (39.2°C), sore throat, painful anterior cervical lymphadenopathy, and tonsillar exudates, without cough or rhinorrhea. A rapid antigen detection test (RADT) is positive for Streptococcus pyogenes (Group A Streptococcus). The child has a documented history of mild hives after amoxicillin 3 years ago (non-severe, non-anaphylactic). What is the primary clinical objective of antibiotic therapy in this patient, and what is an appropriate antimicrobial regimen?